Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.

Kriya Therapeutics, a US-based developer of gene therapies based on research at Stanford University, has closed a $100m series B round led by investment firm Patient Square Capital.
The transaction featured pharmaceutical firm Dexcel Pharma, QVT Financial, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
Woodline Partners LP, CAM Capital, Hongkou Capital, Alumni Ventures and a range of other new but unnamed investors also participated.
Founded in 2019, Kriya Therapeutics is working…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in